Vertero Therapeutics is pioneering science beyond the brain to treat neurodegenerative diseases at their source. Vertero’s development pipeline of differentiated therapies targets the peripheral nervous system to delay onset and slow progression of challenging conditions such as Parkinson’s disease. The company's lead program, VT-5006, is designed to precisely treat a validated target in the gut that feeds the protein aggregation and inflammation implicated in Parkinson’s disease. Vertero is preparing to initiate a Phase 1 clinical trial of VT-5006. The company also has an asset targeting bile acid dysregulation in early development for undisclosed indications.